146 related articles for article (PubMed ID: 22399193)
21. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer.
Sakata H; Murakami S; Hirayama R
Int J Clin Oncol; 2002 Oct; 7(5):312-7. PubMed ID: 12402066
[TBL] [Abstract][Full Text] [Related]
22. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
[TBL] [Abstract][Full Text] [Related]
23. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
24. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
25. The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.
Zerler B
Cancer Cells; 1991 Dec; 3(12):471-9. PubMed ID: 1820093
[TBL] [Abstract][Full Text] [Related]
26. Soluble interleukin-2 receptors in plasma cell dyscrasias.
Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujii H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):749-55. PubMed ID: 2618549
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
28. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
[TBL] [Abstract][Full Text] [Related]
29. The level of interleukin-2 and of soluble interleukin-2 receptor in patients with Balkan nephropathy.
Vöö S; Drugărin D; Mărgineanu F; Koreck A; Negru S; Biriescu A
Roum Arch Microbiol Immunol; 2002; 61(3):207-16. PubMed ID: 14752984
[TBL] [Abstract][Full Text] [Related]
30. Impaired CD25 expression and soluble CD25-IL-2R alpha receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin's disease patients.
Frydecka I; Mazur G
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):127-30. PubMed ID: 8915517
[TBL] [Abstract][Full Text] [Related]
31. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
Tang L; Luo Q; Zhou X; Xia R
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
[TBL] [Abstract][Full Text] [Related]
32. [Serum soluble interleukin-2 receptor in patients with pulmonary mycobacterial diseases].
Tada A; Kawahara S; Horita N; Horiba A; Tamaoki A; Okada C; Mishima Y; Soda R; Takahashi K
Kekkaku; 1999 Jun; 74(6):499-505. PubMed ID: 10423961
[TBL] [Abstract][Full Text] [Related]
33. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
Mehta R; Shah G; Adler W; Kittur D
Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
35. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
36. Serum soluble interleukin 2 receptor alpha and soluble CD8 levels in patients with gynecological malignancies undergoing radiotherapy.
Frydecka I; Rusiecka M; Kuliczkowski K; Kornafel J
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):123-6. PubMed ID: 8915516
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.
Kalmanti M; Karamolengou K; Dimitriou H; Tosca A; Vlachonikolis I; Peraki M; Georgoulias V; Kalmantis T
Int J Hematol; 1993 Apr; 57(2):147-52. PubMed ID: 8494993
[TBL] [Abstract][Full Text] [Related]
38. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
39. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients.
Cimino G; Amadori S; Cava MC; De Sanctis V; Petti MC; Di Gregorio AO; Sgadari C; Vegna L; Cimino G; Mandelli F
Leukemia; 1991 Jan; 5(1):32-5. PubMed ID: 1999955
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of sIL-2R levels in B-cell lymphomas.
Yoshida N; Oda M; Kuroda Y; Katayama Y; Okikawa Y; Masunari T; Fujiwara M; Nishisaka T; Sasaki N; Sadahira Y; Mihara K; Asaoku H; Matsui H; Seto M; Kimura A; Arihiro K; Sakai A
PLoS One; 2013; 8(11):e78730. PubMed ID: 24236041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
